Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT — Stella

Recruiting

Back to SCLC, Limited Stage trials

Trial locations(4 sites)

China

Cancer Hospital of Shandong First Medical University, Jinan

Nanjing Chest Hospital, Nanjing

The First Affiliated Hospital with Nanjing Medical University, Nanjing

The affiliated hospital of qingdao university, Qingdao

Key details

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment target

~25 participants

Started

July 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov